Since the beginning of 2024, PFE stock has underperformed the S&P 500 index, delivering -3% returns compared to the index’s ...

This World Cancer Day, Pfizer Canada ULC, together with Rethink Breast Cancer, Colorectal Cancer Canada, Lung Health ...

The pharmaceutical giant Pfizer will pay nearly $60 million to ... including in the form of speaker honoraria and meals at high-end restaurants, to healthcare professionals to induce them to ...

Currently, the analyst consensus on Pfizer is a Moderate Buy with an average price target of $30.53. The company has a one-year high of $31.54 and a one-year low of $24.48. Currently, Pfizer has ...

We recently compiled a list of the 10 Best High-Yield Dividend Stocks To Invest In. In this article, we are going to take a look at where Pfizer Inc. (NYSE:PFE) stands against the other high-yield ...

the analysts’ consensus rating for Pfizer is Moderate Buy based on seven Buy, 10 Hold, and one Sell ratings over the last three years. With that comes an average price target of $30.40, a high ...

On 16 January 2025, Mr Justice Mellor delivered a judgment in the High Court concerning a patent dispute between Pfizer Limited and GlaxoSmithKline Biologicals S.A along with ID Biomedical Corporation ...

consider the High-Quality portfolio, which has outperformed the S&P, and clocked >91% returns since inception. How Did 2024 Turn Out For Pfizer? Some of the trends were clearly visible for PFE in ...

the Lung Health Foundation is proud to partner with Pfizer, Lung Cancer Canada, and the Quebec Lung Association to address the critical need for equitable high-quality initiatives in metastatic ...

An oncology-focused Pfizer is poised to grow over the coming years. Abundant (and growing) earnings protect the dividend despite an abnormally high yield. The stock's valuation signals that the ...

Jan 15 (Reuters) - Pfizer (PFE.N), opens new tab will sell ... Shares of DBS soared to a record high on Monday after Singapore's largest bank flagged an improvement in net interest income for ...